Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Regn22530

Preclinical

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Primary Open Angle GlaucomaNot yet recruiting

Primary Open Angle GlaucomaPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalNot yet recruiting

Primary Open Angle Glaucoma

NCT07675824

Clinical

Trials by Indication[1]

Primary Open Angle Glaucoma1 trial

A Phase 1/2 Study of REGN22530 in Participants With Primary Open Angle Glaucoma or Ocular Hypertension

Not yet recruiting· Regeneron logo

Regeneron·Preclinical·NCT07675824·271 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regn22530. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Regn22530. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Regeneron

Related News